
Supplements and Featured Publications
- Newsletter - Inflammation, Metabolic Syndrome, and CV Risk Reduction
- Volume 10
- Issue 2 Metab
Faculty Disclosure Statement
Dr Dunbar: Speakers' bureau: Kos, Pfizer; Dr Szapary: Grants/research support: Takeda; Speakers' bureau: Takeda, Pfizer; Dr Haffner: Reported no financial support; Dr Rader: Consultant/grants/research support: Abbott, AstraZeneca, Bristol-Myers Squibb, Fournier, Kos, Merck, Pfizer, Schering-Plough; Speakers' bureau: Abbott, AstraZeneca, Bristol-Myers Squibb, Kos, Merck, Pfizer, Schering-Plough.
This report includes discussion of insulin sensitizers, including metformin and the thiazolidinediones, for preventing type 2 0diabetes, an indication not currently approved by the FDA.
Articles in this issue
about 21 years ago
CE / CMEabout 21 years ago
Commentaryabout 21 years ago
Post Testabout 21 years ago
Metabolic syndrome: A new target of therapy?Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.